【摘要】 目的观察含长春瑞滨和顺铂的改良CHOP方案(CHND方案)治疗复发性难治性非霍奇金淋巴瘤(NHL)的临床疗效和主要不良反应。方法36例复发性难治性NHL病人用长春瑞滨(NVB)和顺铂(DDP)替代CHOP方案中的长春新碱(VCR)和强的松(PDN)组成CHND方案治疗,21天为1周期,至少完成2周期治疗评价疗效。结果全组36例患者均可评价疗效,其中完全缓解率(CR)16.7%,部分缓解率(PR)52.8%,总有效率(RR)69.4%。中位疾病进展时间为15.3个月,中位生存期为20.8个月。不良反应中最常见的为骨髓抑制,其他较为常见的分别为脱发、胃肠道反应等。结论CHND方案可作为复发性难治性NHL的解救治疗方案。更多还原

【Abstract】 Objective To study the clinical efficacy and toxicity of improved CHOP regimen combined with vinorelbine(NVB) and cisplatin(DDP) for patients with recrudescent refractory non-Hodgkin’s lymphoma(NHL).Methods Thirty-six patients with recrudescent refractory NHL were recruited.The improved CHOP regimen substituted vincristine(VCR) and prednisone(PDN) with NVB and DDP.The treatment repeated in every 21 days.The clinical efficacy and toxicity were assessed after at least 2 cycles of chemotherapy.Results The overall response rate(RR) was 69.4%,complete response(CR)16.7%,patial response(PR)52.8%.Median progressive time was 15.3 months.Median survival time was 20.8 months.The most common toxic effect was myelosuppression.Conclusion CHND regimen can be used as the second choice for recrudescent refractory NHL.更多还原